A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
Active, not recruiting · NCT05662397 · Registry updated 2025-02-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, neoplasm, refractory malignant neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2025-02-04 | NCT05662397 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| HotSpot Therapeutics, Inc | 1 |
14 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Abramson Cancer Center | Philadelphia | United States | 11 |
| Clínica Universidad de Navarra | Madrid | Spain | 6 |
| Clínica Universidad de Navarra (Pamplona) | Pamplona | Spain | 1 |
| Comprehensive Cancer Centers of Nevada | Las Vegas | United States | 34 |
| Florida Cancer Specialists | Sarasota | United States | 47 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1 |
| Montefiore Einstein Comprehensive Cancer Center | The Bronx | United States | 9 |
| NEXT Oncology Barcelona IOB Hospital Quirónsalud | Barcelona | Spain | 1 |
| NEXT Oncology Hospital Universitario Quirónsalud Madrid | Madrid | Spain | 1 |
| Princess Margaret Cancer Center | Toronto | Canada | 30 |
| Providence Cancer Institute of Oregon | Portland | United States | 2 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |
| University of Ottawa | Ottawa | Canada | 17 |
| University of Pittsburgh (UPMC), Hillman Cancer Center | Pittsburgh | United States | 1 |